Medical Developments International returned to EBIT profitability in FY26 as Penthrox volumes strengthened across Australian hospitals and Europe. The company now faces the less glamorous test of converting regulatory progress into repeatable demand while absorbing weaker Respiratory sales and new amortisation costs.
- Revenue up 9% to $42.6 million
- Penthrox hospital volumes up 28% in Australia
- European in-market demand up 18%
- Free cash flow improved to $4.2 million
- Respiratory revenue fell 15% in FY26
Penthrox growth drives FY26 earnings recovery
Medical Developments International Limited (ASX:MVP) finished FY26 with a small profit, materially stronger cash generation and a more convincing growth engine in Penthrox. Group revenue rose 9% to $42.6 million, EBIT moved from a $48,000 loss to a $215,000 profit, and net profit after tax increased to $626,000 from $94,000.
The headline improvement was not evenly spread across the business. Pain Management revenue climbed 21% to $31.6 million, while Respiratory revenue fell 15% to $10.9 million as softer demand, particularly in the United States, outweighed higher pricing. The contrast leaves Penthrox carrying more of the investment case than it did a year ago.
The full-year report confirms the figures from the company’s FY26 results announcement, which reported the same 9% revenue growth and $0.6 million net profit. In Australia, Penthrox volumes rose 9% overall to 359,000 units, with hospital volumes increasing 28%. Revenue from Australian Penthrox sales rose 16%, helped by pricing changes that contributed a stated $1 million benefit to earnings.
European paediatric approval expands the addressable market
Europe supplied a second leg of the Penthrox story. In-market demand increased 18% to 382,000 units, with growth reported across the UK and Ireland, France and the Nordic region. The company also secured approval for the paediatric indication in the UK and every EU member state, extending use to children aged six and older and, according to the report, broadening the addressable market by approximately 20%.
That regulatory milestone builds on the European paediatric approval reported in the prior financial year. Medical Developments also points to publication of the MAGPIE paediatric study and a health-economic analysis supporting Penthrox use in emergency departments. These developments are presented as tools for adoption, rather than as guaranteed revenue outcomes.
European revenue growth also needs to be read carefully. Sales to partners benefited partly from higher inventory holdings during the transition to partner supply in France and Switzerland. Medical Developments expects that stocking benefit not to recur in FY27, while approximately $1 million of amortisation linked to European paediatric registration costs is expected to weigh on earnings.
Cash generation strengthens despite Respiratory weakness
Cashflow provided the clearest improvement in the report. Operating cashflow swung from an outflow of $43,000 to an inflow of $5.8 million, while free cash flow reached $4.2 million, up $5.8 million on the prior year. The change was helped by a $5.2 million year-on-year improvement in working capital, including lower inventories and stronger collections.
At 30 June, the group held $14.4 million in cash and a further $7 million in a term deposit maturing in November 2026, giving cash and short-term deposits of $21.4 million. It had no borrowings. The balance sheet therefore gives the company room to fund its stated FY27 capital expenditure of about $1.5 million, although the report does not provide formal earnings guidance.
FY27 must prove demand is more than inventory timing
Management expects higher in-market Penthrox demand in FY27, supported by the European paediatric indication and health-economic data, alongside stable Respiratory demand. It also plans to deepen hospital adoption in Australia, generate additional real-world evidence, strengthen partner engagement and assess selected new markets, including potential US pathways for Penthrox.
The caution sits in the bridge between those ambitions and the reported numbers. Respiratory revenue declined in every major region, foreign exchange movements reduced earnings by $0.9 million, and the company continues to monitor Middle East supply disruption and US tariff impacts. The next set of results will show whether Australian hospital momentum and European demand can offset the disappearing stocking benefit, the expected amortisation charge and continued softness in Respiratory.
Bottom Line?
The balance sheet has bought Medical Developments time; FY27 will test whether Penthrox adoption can deliver recurring growth without the boost from partner inventory stocking.
Questions in the middle?
- Can the European paediatric indication translate into sustained in-market demand after FY26’s inventory benefit fades?
- Will Australian hospital adoption continue to offset weakness in the Respiratory business, particularly in the US?
- How much of FY27 earnings and cashflow will be absorbed by the expected $1 million amortisation charge and supply-chain risks?